Page 58 - Read Online

Koukourakis et al. J Cancer Metastasis Treat 2022;8:38 https://dx.doi.org/10.20517/2394-4722.2022.43 Page 19 of 23

15. Weniger M, Honselmann KC, Liss AS. The Extracellular matrix and pancreatic cancer: a complex relationship. Cancers (Basel)
2018;10:316. DOI PubMed PMC
16. Amit M, Gil Z. Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine
deaminase. Oncoimmunology 2013;2:e27231. DOI PubMed PMC
17. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport
and metabolism in human pancreatic cancer cells. Br J Cancer 2007;96:457-63. DOI PubMed PMC
18. Komori S, Osada S, Mori R, et al. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Pancreas 2010;39:1284-92. DOI PubMed
19. Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a Determinant of response to irinotecan and neoadjuvant FOLFIRINOX
therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst 2015;107:djv132. DOI PubMed PMC
20. Tezuka S, Ueno M, Kobayashi S, et al. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for
the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer. Am J Cancer Res 2018;8:2096-105.
PubMed PMC
21. Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of taxane resistance. Cancers (Basel) 2020;12:3323. DOI
PubMed PMC
22. Shah VM, Sheppard BC, Sears RC, Alani AW. Hypoxia: friend or foe for drug delivery in pancreatic cancer. Cancer Lett
2020;492:63-70. DOI PubMed PMC
23. Moir JA, Mann J, White SA. The role of pancreatic stellate cells in pancreatic cancer. Surg Oncol 2015;24:232-8. DOI PubMed
24. Arnold CR, Mangesius J, Skvortsova II, Ganswindt U. The role of cancer stem cells in radiation resistance. Front Oncol 2020;10:164.
DOI PubMed PMC
25. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. DOI PubMed
26. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or
metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer
2002;94:902-10. PubMed
27. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent
gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-51. DOI
PubMed
28. Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
Br J Cancer 2014;111:1132-8. DOI PubMed PMC
29. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
DOI PubMed
30. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in
patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-8. DOI PubMed
31. Li Q, Yan H, Liu W, Zhen H, Yang Y, Cao B. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the
management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e104346. DOI
PubMed PMC
32. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic
cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol
2005;23:1228-36. DOI PubMed
33. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
2011;364:1817-25. DOI PubMed
34. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level
meta-analysis. Lancet Oncol 2016;17:801-10. DOI PubMed PMC
35. Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in
resectability in 60% of the patients. Ann Surg 2016;264:457-63. DOI PubMed
36. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced
pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-54. DOI PubMed PMC
37. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med
2013;369:1691-703. DOI PubMed PMC
38. Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant
FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg 2019;270:400-13. DOI PubMed
39. Arima S, Kawahira M, Shimokawa M, et al. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX in locally advanced, unresectable
pancreatic cancer: a multicenter observational study (NAPOLEON study). Pancreas 2021;50:957-64. DOI PubMed
40. Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a
multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020;5:285-94. DOI PubMed
41. Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by
FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre,